Business
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK, May 07, 2026--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
About this update from Evommune, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2c6142b6f22a670286e0b6f63da81721"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I_cIWYWN4qdncVd4udUmKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/2c6142b6f22a670286e0b6f63da81721","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/IqtVRidNkq2ZGjmS_2dSIw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/2c6142b6f22a670286e0b6f63da81721","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5rOIRxU2sXC7b1Z51LqhBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/2c6142b6f22a670286e0b6f63da81721","width":1024,"height":512}},"lazy":false},{"type":"text","content":"‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"‑ Phase 2b clinical trial evaluating a subcutaneous formulation of EVO301 in AD planned, following positive proof-of-concept (POC) data reported in February 2026","length":161,"tagName":"p","attribs":{}},{"type":"text","content":"‑ Plans to initiate a Phase 2b dose-ranging clinical trial of EVO756 in migraine prophylaxis in mid-2026","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"PALO ALTO, Calif. & NEW YORK, May 07, 2026--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.","length":382,"tagName":"p"},{"type":"text","content":""We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for EVO756 in CSU in June and in AD in the third quarter of 2026. We also expect to initiate a Phase 2b clinical trial in a third indication, migraine prophylaxis, in...